(Q40149030)

17 September 2017

1 reference

title

The clinical pharmacology of methotrexate (English)

1 reference

17 September 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

3 October 2023

author name string

J. H. Schornagel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6342775

3 October 2023

J. G. McVie

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6342775

3 October 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6342775

3 October 2023

publication date

1 March 1983

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:S0305737283800322?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

https://api.elsevier.com/content/article/PII:S0305737283800322?httpAccept=text/plain

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

3 October 2023

published in

Cancer Treatment Reviews

1 reference

17 September 2017

10

1 reference

17 September 2017

53-75

1 reference

17 September 2017

1

1 reference

Limited effectiveness of in vitro high-dose methotrexate and leucovorin to overcome resistance in L1210 leukemia cells with elevations of dihydrofolate reductase

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

The clinical pharmacology of antineoplastic agents (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Threshold Methotrexate Concentration for In Vivo Inhibition of DNA Synthesis in Normal and Tumorous Target Tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Continuous infusion of methotrexate in children with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Effect of pleural effusion on high-dose methotrexate kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Inhibition of dihydrofolate reductase by methotrexate: a new look at an old problem

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Detective transport of amethopterin (methotrexate) as a mechanism of resistance to the antimetabolite in L5178Y leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Selection of wild-type revertants from methotrexate-resistant cells containing an altered dihydrofolate reductase.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Methotrexate revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

A methotrexate insensitive variant of folate reductase present in two lines of methotrexate-resistant L5178Y cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

The characteristics of the membrane transport of amethopterin and the naturally occurring folates

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

The effect of photon irradiation on blood-brain barrier permeability to methotrexate in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Methotrexate and hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Enhancement of the therapeutic effectiveness of methotrexate and protection of normal proliferating tissues with purines and pyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Unbalanced Deoxyribonucleotide Synthesis Caused by Methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Hemodialysis and enzymatic cleavage of methotrexate in man

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Achievement of long duration methotrexate exposure with concurrent low dose thymidine protection: Influence on methotrexate pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Pharmacokinetics of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Pharmacokinetics of methotrexate administered via the hepatic artery

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Studies with a mathematical model of folate metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Accumulation of methotrexate diglutamate in human liver during methotrexate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

High-pressure liquid chromatography analysis of methotrexate polyglutamates in cultured human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Cytogenetic effects of methotrexate on human cells in vivo: comparison between results obtained by chromosome studies on bone-marrow cells and blood lymphocytes and by the micronucleus test

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Natural resistance to methotrexate in human melanomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Change in transfer rate of methotrexate from spinal fluid to plasma during intrathecal therapy in children and adults

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Dose dependent methotrexate elimination following bolus intravenous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Cell kinetic factors, single drugs and combination

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

The effect of organic acids on renal clearance of methotrexate in man

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Methotrexate meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

The pharmacokinetics of cyclophosphamide in man following treatment with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

5-Fluorouracil and methotrexate combination chemotherapy: the effect of drug scheduling

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Methotrexate enteropathy?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Enterotoxic effect of methotrexate: does it influence the drug's absorption in children with acute lymphoblastic leukaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Absorption of methotrexate under standardized conditions in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Extracellular recovery of methotrexate-polyglutamates following efflux from L1210 leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Effects of sulfhydryl inhibitors upon transport of folate compounds into L1210 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Triamterene-induced elevation of dihydrofolate reductase activity in human leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Immunosuppressive and Cytotoxic Chemotherapy: Long-Term Complications

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Gene amplification and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

The enhancement effect of irradiation by methotrexate. Report of three complications

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Methotrexate-induced pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

The protein binding of methotrexate by the serum of normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Enhancement of methotrexate absorption by subdivision of dose

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Some Observations on the Reversibility of Methotrexate Toxicity in Normal Proliferating Tissues2

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Bioavailability of methotrexate: implications for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Antimetabolite-metabolite combination cancer chemotherapy. Effects of intraarterial methotrexate-intramuscular Citrovorum factor therapy in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

The reversal of methotrexate toxicity by thymidine with maintenance of antitumour effects

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Rapid plasma clearance and reduced rate and extent of urinary elimination of parenterally administered methotrexate as a result of severe vomiting and diarrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

1 reference

7 January 2021

Neurotoxicity of commonly used antineoplastic agents (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Refractory acute leukaemia in adults treated with sequential colaspase and high-dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2883%2980032-2

7 January 2021

Interaction of chemotherapeutic agents with methotrexate and 5-fluorouracil and its effect on de novo DNA synthesis

1

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Antimetabolites in the central nervous system

3 October 2023

3

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Some observations on the human pharmacology of methotrexate

3 October 2023

5

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Schedule-dependent synergism of methotrexate and vincristine against murine L1210 leukemia

3 October 2023

11

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Methotrexate absorption in children with acute lymphoblastic leukemia

3 October 2023

17

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

The prevention of methotrexate toxicity by thymidine infusions in humans

3 October 2023

24

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

High-dose methotrexate in acute lymphocytic leukemia

3 October 2023

33

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Effects of 2,4-dinitrophenol and other metabolic inhibitors on the bidirectional carrier fluxes, net transport, and intracellular binding of methotrexate in Ehrlich ascites tumor cells

3 October 2023

37

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Formation of methotrexate polyglutamates in rat hepatocytes

3 October 2023

41

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Anaphylactic reaction to high-dose methotrexate

3 October 2023

42

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

The mechanism of action of methotrexate. I. Interaction with a low-affinity intracellular site required for maximum inhibition of deoxyribonucleic acid synthesis in L-cell mouse fibroblasts

3 October 2023

46

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Effects of methotrexate on cellular metabolism: some critical elements in the drug-cell interaction

3 October 2023

48

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man

3 October 2023

55

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate

3 October 2023

56

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Thymidine rescue of high-dose methotrexate in humans

3 October 2023

60

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Thymidine requirements for the rescue of patients treated with high-dose methotrexate

3 October 2023

61

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate

3 October 2023

62

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Phase I trial of high-dose methotrexate with modified citrovorum factor rescue

3 October 2023

70

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors

3 October 2023

73

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man

3 October 2023

86

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Role of thymidylate synthetase activity in development of methotrexate cytotoxicity

3 October 2023

89

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Competitive protein binding assay for methotrexate

3 October 2023

94

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides

3 October 2023

98

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion

3 October 2023

99

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells

3 October 2023

113

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Inhibition of methotrexate polyglutamate accumulation in cultured human cells

3 October 2023

114

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Methotrexate polyglutamate synthesis by cultured human breast cancer cells

3 October 2023

117

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine

3 October 2023

120

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia

3 October 2023

123

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Increased accumulation of methotrexate by murine tumor cells in vitro in the presence of probenecid which is mediated by a preferential inhibition of efflux

3 October 2023

124

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Effect of gentamicin and irradiation on the toxicity of high-dose methotrexate in rats

3 October 2023

127

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue

3 October 2023

132

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry

3 October 2023

139

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Antifolates: in vivo kinetic considerations

3 October 2023

153

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

Relative biochemical aspects of low and high doses of methotrexate in mice

3 October 2023

154

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(83)80032-2

3 October 2023

Identifiers

1 reference

17 September 2017

1 reference